Raymond James Upgrades Tvardi Therapeutics to Outperform, Announces $10 Price Target

Benzinga Newsdesk www.benzinga.com Positive 91.4%

Neg 0% Neu 0% Pos 91.4%

Raymond James analyst Ryan Deschner upgrades Tvardi Therapeutics (NASDAQ:TVRD) from Market Perform to Outperform and announces $10 price target.